Jonathan S Chávez-Iñiguez1,2, Jorge L Poo3, Miguel Ibarra-Estrada4, Leonel García-Benavides2,5, Guillermo Navarro-Blackaller1,2, Cynthia Cervantes-Sánchez1,2, Eduardo Nungaray-Pacheco1,2, Ramón Medina-González1,2, Juan Armendariz-Borunda2,6,7, Guillermo García-García1,2. 1. Servicio de Nefrología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico. 2. Universidad de Guadalajara, Centro Universitario de Ciencias de La Salud CUCS, Guadalajara, Jalisco, Mexico. 3. Unidad de Investigación, ITESM-CCM, Mexico City, Mexico. 4. Servicio de Unidad de Terapia Intensiva, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico. 5. Universidad de Guadalajara, Centro Universitario de Tonalá CUTonalá, Tonalá, Jalisco, Mexico. 6. Instituto de Biología Molecular en Medicina, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. 7. Tecnologico de Monterrey, Campus Guadalajara, Monterrey, Mexico.
Abstract
BACKGROUND: There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. METHODS: This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultation at the Civil Hospital of Guadalajara, in addition to the usual treatment of AKI associated with sepsis; patients were randomized to receive either PR-PFD at 1,200 mg/day (group A) or 600 mg/day (group B) or a matched placebo for 7 consecutive days. The primary objective was the decrease in serum creatinine (sCr) and increase in urinary volume (UV); the secondary objectives were changes in serum electrolytes, acid-base status, and mortality. RESULTS: Between August 2016 and August 2017, 88 patients were randomized. The mean age was 54 (17 ± SD) years, and 47% were male. The main site of infection was the lung (39.8%), septic shock was present in 39.1% of the cases, and the mean SOFA score was 8.8 points. 28 patients received PFD 1,200 mg, 30 patients received PFD 600 mg, and 30 patients received placebo. During the study, sCr did not differ among the groups. The reversion rate of sCr, UV, and mortality was not different among the groups (p=0.70, p=0.47, and p=0.38, respectively). Mild adverse events were not different among the groups. CONCLUSION: PR-PFD did not improve the clinical course of sAKI and seemed to be safe in terms of adverse events. This trial is registered with NCT02530359.
BACKGROUND: There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. METHODS: This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultation at the Civil Hospital of Guadalajara, in addition to the usual treatment of AKI associated with sepsis; patients were randomized to receive either PR-PFD at 1,200 mg/day (group A) or 600 mg/day (group B) or a matched placebo for 7 consecutive days. The primary objective was the decrease in serum creatinine (sCr) and increase in urinary volume (UV); the secondary objectives were changes in serum electrolytes, acid-base status, and mortality. RESULTS: Between August 2016 and August 2017, 88 patients were randomized. The mean age was 54 (17 ± SD) years, and 47% were male. The main site of infection was the lung (39.8%), septic shock was present in 39.1% of the cases, and the mean SOFA score was 8.8 points. 28 patients received PFD 1,200 mg, 30 patients received PFD 600 mg, and 30 patients received placebo. During the study, sCr did not differ among the groups. The reversion rate of sCr, UV, and mortality was not different among the groups (p=0.70, p=0.47, and p=0.38, respectively). Mild adverse events were not different among the groups. CONCLUSION: PR-PFD did not improve the clinical course of sAKI and seemed to be safe in terms of adverse events. This trial is registered with NCT02530359.
Authors: Sara Nisula; Kirsi-Maija Kaukonen; Suvi T Vaara; Anna-Maija Korhonen; Meri Poukkanen; Sari Karlsson; Mikko Haapio; Outi Inkinen; Ilkka Parviainen; Raili Suojaranta-Ylinen; Jouko J Laurila; Jyrki Tenhunen; Matti Reinikainen; Tero Ala-Kokko; Esko Ruokonen; Anne Kuitunen; Ville Pettilä Journal: Intensive Care Med Date: 2013-01-05 Impact factor: 17.440
Authors: Jean-Louis Vincent; Yasser Sakr; Charles L Sprung; V Marco Ranieri; Konrad Reinhart; Herwig Gerlach; Rui Moreno; Jean Carlet; Jean-Roger Le Gall; Didier Payen Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: Peter Pickkers; Marlies Ostermann; Michael Joannidis; Alexander Zarbock; Eric Hoste; Rinaldo Bellomo; John Prowle; Michael Darmon; Joseph V Bonventre; Lui Forni; Sean M Bagshaw; Miet Schetz Journal: Intensive Care Med Date: 2017-01-30 Impact factor: 17.440
Authors: Eric A J Hoste; Gilles Clermont; Alexander Kersten; Ramesh Venkataraman; Derek C Angus; Dirk De Bacquer; John A Kellum Journal: Crit Care Date: 2006-05-12 Impact factor: 9.097